Ironwood Pharmaceuticals | IRWD - Equity Capital And Reserves


Ironwood Pharmaceuticals reported $-217.14M in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 1.25B 20.68M Mar/2026
Agios Pharmaceuticals USD 1.11B 84M Mar/2026
Akebia Therapeutics USD 27.38M 5.24M Mar/2026
Almirall EUR 1.49B 24.03M Dec/2025
Alnylam Pharmaceuticals USD 1.08B 286.2M Mar/2026
Amarin USD 449.41M 9.87M Mar/2026
Ardelyx USD 148.62M 18.33M Mar/2026
Astellas Pharma JPY 1.83T 65.92B Mar/2026
AstraZeneca USD 47.33B 1.33B Mar/2026
Charles River Laboratories USD 2.9B 265.94M Mar/2026
Coherus Biosciences USD 61.01M 26.76M Dec/2025
Emergent BioSolutions USD 649.3M 47.9M Dec/2023
Halozyme Therapeutics USD 219.64M 170.82M Mar/2026
Incyte USD 5.62B 455.37M Mar/2026
Ironwood Pharmaceuticals USD -217.14M 44.69M Mar/2026
Karyopharm Therapeutics USD -292.93M 23.67M Dec/2025
Lexicon Pharmaceuticals USD 202.86M 95.32M Mar/2026
MacroGenics USD 21.2M 34.39M Mar/2026
Moderna USD 7.41B 1.24B Mar/2026
Myriad Genetics USD 337.4M 30.6M Mar/2026
Pacira USD 653.89M 39.22M Mar/2026
PTC Therapeutics USD -180.46M 24.85M Mar/2026
Puma Biotechnology USD 115.27M 10.55M Sep/2025
Sarepta Therapeutics USD 1.51B 364.48M Mar/2026
Takeda JPY 7.77T 129.5B Mar/2026
Ultragenyx Pharmaceutical USD -236M 156M Mar/2026
Vanda Pharmaceuticals USD 327.19M 138.81M Dec/2025